Dr Berk and Dr Dodd have financial interests/arrangements or affiliations with the following organizations that could be perceived as a real or apparent conflict of interest with this paper. Dr Berk has received grant/research support from the Stanley Foundation, Beyond Blue, Geelong Regional Medical Foundation, Organon, Eli Lilly & Co., Bristol-Myers Squibb, Novartis; consultant for GlaxoSmithKline, Janssen Cilag, Bristol-Myers Squibb, Eli Lilly & Co., Lundbeck, AstraZeneca; and serves on the speakers bureau for GlaxoSmithKline, Janssen Cilag, Bristol-Myers Squibb, Eli Lilly & Co., Wyeth, Pfizer, Sanofi Synthelabo, Lundbeck, AstraZeneca, Solvay, Organon. Dr Dodd has received grant/research support from Eli Lilly & Co., Novartis, Bristol-Myers Sqibb, Organon.
Bipolar II disorder: a review
Article first published online: 14 JAN 2005
Volume 7, Issue 1, pages 11–21, February 2005
How to Cite
Berk, M. and Dodd, S. (2005), Bipolar II disorder: a review. Bipolar Disorders, 7: 11–21. doi: 10.1111/j.1399-5618.2004.00152.x
- Issue published online: 14 JAN 2005
- Article first published online: 14 JAN 2005
- Received 2 December 2003, revised and accepted for publication 23 August 2004
- bipolar disorder;
- bipolar II;
Objectives: To review the current knowledge of bipolar II disorder.
Methods: Literature was reviewed after conducting a Medline search and a hand search of relevant literature.
Results: Bipolar II disorder is a common disorder, with a prevalence of approximately 3–5%. Distinct clinical features of bipolar II disorder have been described. The key to diagnosis is the recognition of past hypomania, while depression is the typical presenting feature of the illness. This is responsible for a significant rate of missed diagnosis, and consequent management according to unipolar guidelines. It is unclear if bipolar II disorder is over-represented amongst resistant depression populations and if abrupt offset of antidepressant action is a phenomenon over represented in bipolar II disorder, reflecting induction of predominantly depressive cycling. A few mood-stabilizer studies available provide provisional suggestion of utility. A supportive role for psychosocial therapies is suggested, however, there is a sparsity of published studies specific to bipolar II disorder cohorts. A small number of short-term antidepressant trials have suggested efficacy, however, compelling long-term maintenance data is absent.
Conclusions: An emerging literature on the specific clinical signature and management of the disorder exists, however, this is disproportionately small relative to the epidemiology and clinical significance of the disorder.